1Amending the act of April 14, 1972 (P.L.233, No.64), entitled
2"An act relating to the manufacture, sale and possession of
3controlled substances, other drugs, devices and cosmetics;
4conferring powers on the courts and the secretary and
5Department of Health, and a newly created Pennsylvania Drug,
6Device and Cosmetic Board; establishing schedules of
7controlled substances; providing penalties; requiring
8registration of persons engaged in the drug trade and for the
9revocation or suspension of certain licenses and
10registrations; and repealing an act," further providing for
11schedules of controlled substances.

12The General Assembly of the Commonwealth of Pennsylvania
13hereby enacts as follows:

14Section 1. Section 4(1)(vii) of the act of April 14, 1972
15(P.L.233, No.64), known as The Controlled Substance, Drug,
16Device and Cosmetic Act, amended June 20, 2011 (P.L.86, No.7),
17is amended and the paragraph is amended by adding a subparagraph
18to read:

19Section 4. Schedules of Controlled Substances.--The
20following schedules include the controlled substances listed or
21to be listed by whatever official name, common or usual name,

1chemical name, or trade name designated.

2(1) Schedule I--In determining that a substance comes within
3this schedule, the secretary shall find: a high potential for
4abuse, no currently accepted medical use in the United States,
5and a lack of accepted safety for use under medical supervision.
6The following controlled substances are included in this
7schedule:

8* * *

9(iii.1) Any compound, except bupropion or compounds listed
10under a different schedule, or compounds used within legitimate
11and approved medical research, structurally derived from 2-
12aminopropan-1-one by substitution at the 1-position with phenyl,
13naphthyl or thiophenen ring systems, whether or not the compound
14is further modified in any of the following ways:

151. By substitution in the ring system to any extent with
16alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl or halide
17substituents whether or not further substituted in the ring
18system by one or more other univalent substituents.

192. By substitution at the 3-position with an acyclic alkyl
20substituent.

213. By substitution at the 2-amino nitrogen atom with alkyl,
22dialkyl, benzyl or methoxybenzyl groups.

234. By inclusion of the 2-amino nitrogen atom in a cyclic
24structure.

25* * *

26(vii) [Synthetic cannabinoids or any material, compound, 
27mixture or preparation which contains any quantity of the 
28following substances, including their analogues, congeners, 
29homologues, isomers, salts and salts of analogues, congeners, 
30homologues and isomers, as follows:

11. CP 47,497 and homologues, 2-[(1R,3S)-3-
2hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol).

32. HU-210, [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
4methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo[c] chromen-1-
5ol)].

63. HU-211, (dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-
7dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
8tetrahydrobenzo[c]chromen-1-ol).

94. JWH-018, 1-Pentyl-3-(1-naphthoyl)indole.

105. JWH-019, 1-Hexyl-3-(1-naphthoyl)indole.

116. JWH-073, 1-Butyl-3-(1-naphthoyl)indole.

127. JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)-
13naphthalen-1-ylmethanone.

148. JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]

15Synthetic cannabinoids including any material, compound, mixture
16or preparation that is not listed as a controlled substance in
17Schedule I through V, is not a Federal Food and Drug
18Administration approved drug or used within legitimate and
19approved medical research and which contains any quantity of the
20following substances, their salts, isomers, whether optical
21positional or geometric, analogues, homologues and salts of
22isomers, analogues and homologues, unless specifically excepted,
23whenever the existence of these salts, isomers, analogues,
24homologues and salts of isomers, analogues and homologues if
25possible within the specific chemical designation:

261. Tetrahydrocannabinols or tetrahydrocannabinols which is
27naturally contained in a plant of the genus cannabis as well as
28synthetic equivalents of the substances contained in the plant
29or in the resinous extractives of Cannabis or synthetic
30substances, derivatives and their isomers with similar chemical

1structure and or pharmacological activity such as the following:

2(A) Delta 1 cis or trans tetrahydrocannabinol and their
3optical isomers.

4(B) Delta 6 cis or trans tetrahydrocannabinol and their
5optical isomers.

6(C) Delta 3, 4 cis or their trans tetrahydrocannabinol and
7their optical isomers.

82. Naphthoxylindoles or any compound containing a 3-(-1-
9napthoyl) indole structure with substitution at the nitrogen
10atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
11alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
12piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
13pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
14(terahydropyran-4-yl) methyl group, whether or not further
15substituted in the indole ring to any extent and whether or not
16substituted in the naphthyl ring to any extent. This shall
17include the following:

18(A) JWH 015.

19(B) JWH 019.

20(C) JWH 073.

21(D) JWH 081.

22(E) JWH 122.

23(F) JWH 200.

24(G) JWH 210.

25(H) JWH 398.

26(I) AM2201.

27(J) WIN 55 212.

283. Naphylmethylindoles or any compound containing a 1H-
29indol-3-yl-(1-naphthyl) methanae methane structure with a
30substition at the nitrogen atom of the indole ring by an alkyl,

1haloalkyl, cyanoalkyl, alkenyl, cycloalkymethyl,
2cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, 2-(4-
3morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-
4methyl-3-morpholinyl) methyl or (tetrahydropyran-4-yl) methyl
5group, whether or not further substituted in the indole ring to
6any extent and whether or not substituted in the naphthyl ring
7to any extent. This shall include JWH 175 and JWH 184.

84. Naphthoylpyrroles or any compound containing a 3-(1-
9naphthoyl) pyrrole structure with substitution at the nitrogen
10atom of the pyrrole ring by alkyl, haloalkyl, cyanoalykl,
11alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
12piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
13pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
14(tetrahydropyran-4-yl) methyl group, whether or not further
15substituted in the pyrrole ring to any extent and whether or not
16substituted in the naphthyl ring to any extent. This shall
17include JWH 307.

185. Naphthylmethylindenes or any compound containing a
19naphthylideneindene structure with substitution at the 3-
20position of the indene ring by an alkyl, haloalkyl, cyanoalkyl,
21alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
22piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
23pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl)methyl or
24(tetraydropyran-4-yl) methyl group, whether or not further
25substituted in the indene ring to any extent and whether or not
26substituted in the naphthyl ring to any extent. This shall
27include JWH 176.

286. Phenylacetylindoles or any compound containing a 3-
29phenylacetylindole structure with substitution at the nitrogen
30atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,

1alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
2piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
3pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
4(tetrahydropyan-4-yl) methyl group, whether or not further
5substituted in the indole ring to any extent and whether or not
6substituted in the phenyl ring to any extent. This shall include
7the following:

8(A) RCS-8 or SR-18.

9(B) JWH 250.

10(C) JWH 203.

11(D) JWH 251.

12(E) JWH 302.

137. Cyclohexylphenols or any compound containing a 2-(3-
14hydroxycyclohexyl) phenol structure with a substitution at the
155-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl,
16alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
17piperininyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
18pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
19(tetrahydropyran-4-yl) methyl group, whether or not substituted
20in the cyclohexyl ring to any extent. This shall include the
21following:

22(A) CP 47, 497 and its homologues and analogs.

23(B) Cannabicyclohexanol.

24(C) CP 55, 940.

258. Benzoylindoles or any compound containing a 3-(benzoyl)
26indole structure with substitution at the nitrogren atom of the
27indole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,
28cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)
29methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl)
30methyl, 1-(N-methyl-3- morpholinyl) methyl or (tetrahydropyran-

14-yl) methyl group, whether or not further substituted in the
2indole ring to any extent and whether or not substituted in the
3phenyl ring to any extent. This shall include the following:

4(A) Am 694.

5(B) Pravadoline WIN 48098.

6(C) RCS 4.

7(D)AM-679.

89. [2,3-Dihydro-5 methyl-3-(4-morpholinylmethyl ) pyrrolo
9[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-napthalenymethanone. This
10shall include WIN 55, 212-2.

1110. (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3(2-
12methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo [c]chromen-1-
13old 7370. This shall include HU 210 and HU 211.

1411. Adamantoylindoles or any compound containing a 3-(-
151adamtoyl) indole structure with substitution at the nitrogen
16atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
17alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
18piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
19pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
20(tetrahydropyran-4-yl) methyl group, whether or not further
21substituted in the adamantyl ring system of any extent. This
22shall include AM 1248.

2312. Tetramethylcyclopropanoylindoles or any compound
24containing a 3-tetramethylcyclopropylindole structure with
25substitution at the nitrogen atom of the indole ring by analkyl,
26haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
27cycloalkylethy, 1-(N-methyl-2-piperidinyl) methyl, 2-(4-
28morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-
29methyl-3-morpholinyl) methyl or (tetrahydropyran-4-yl) methyl
30group whether or not further substituted in the indole ring to

1any extent and whether or not substituted in the
2tetramethylcyclopropanoyl ring to any extent. This shall include
3UR-144.

413. Any other synthetic chemical compound that is a
5cannabinoid receptor agonist and mimics the pharmacological
6effect of the naturally occurring cannabinoids that is not
7listed in Schedules II through V, not an Federal Food and Drug
8Administration approved drug or used within legitimate, approved
9medical research.

10* * *

11Section 2. This act shall take effect in 60 days.